ketoconazole has been researched along with Adrenal Gland Hypofunction in 16 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome." | 9.30 | Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. ( Auchus, RJ; Biller, BMK; Cohen, F; Elenkova, A; Feelders, RA; Fleseriu, M; Geer, EB; Greenman, Y; Pivonello, R; Salvatori, R; Witek, P, 2019) |
| "Orally administered ketoconazole may rarely induce liver injury and adrenal insufficiency." | 8.12 | Arylacetamide deacetylase knockout mice are sensitive to ketoconazole-induced hepatotoxicity and adrenal insufficiency. ( Fukami, T; Hirosawa, K; Honda, S; Kisui, F; Konishi, K; Nagaoka, M; Nakajima, M; Nakano, M; Ogiso, T; Sakai, Y; Tashiro, K; Yamada, T, 2022) |
| "Persistent adrenal insufficiency secondary to ketoconazole therapy has not previously been documented." | 7.67 | Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. ( Best, TR; Bussell, KL; Jenkins, JK; Murphy, FY; Nicks, SA; Vesely, DL, 1987) |
| "Ketoconazole is a common and effective adjuvant therapy for hypercortisolism, but the major concern is liver enzyme dysfunction." | 5.37 | Pseudotumor cerebri during Cushing's disease treatment with ketoconazole. ( Boschi, V; Costa, TG; Costenaro, F; Czepielewski, MA; Ferreira, NP; Rodrigues, TC; Schuch, T, 2011) |
| "Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome." | 5.30 | Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. ( Auchus, RJ; Biller, BMK; Cohen, F; Elenkova, A; Feelders, RA; Fleseriu, M; Geer, EB; Greenman, Y; Pivonello, R; Salvatori, R; Witek, P, 2019) |
| "Orally administered ketoconazole may rarely induce liver injury and adrenal insufficiency." | 4.12 | Arylacetamide deacetylase knockout mice are sensitive to ketoconazole-induced hepatotoxicity and adrenal insufficiency. ( Fukami, T; Hirosawa, K; Honda, S; Kisui, F; Konishi, K; Nagaoka, M; Nakajima, M; Nakano, M; Ogiso, T; Sakai, Y; Tashiro, K; Yamada, T, 2022) |
| "Persistent adrenal insufficiency secondary to ketoconazole therapy has not previously been documented." | 3.67 | Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. ( Best, TR; Bussell, KL; Jenkins, JK; Murphy, FY; Nicks, SA; Vesely, DL, 1987) |
| "Ketoconazole was administered as a single daily oral dose of 200 mg to 12 patients with chronic mucocutaneous candidosis (CMC) of autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED)." | 2.66 | Ketoconazole is effective against the chronic mucocutaneous candidosis of autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED). ( Ahonen, P; Kahanpää, A; Myllärniemi, S; Perheentupa, J, 1986) |
| "Ketoconazole is a common and effective adjuvant therapy for hypercortisolism, but the major concern is liver enzyme dysfunction." | 1.37 | Pseudotumor cerebri during Cushing's disease treatment with ketoconazole. ( Boschi, V; Costa, TG; Costenaro, F; Czepielewski, MA; Ferreira, NP; Rodrigues, TC; Schuch, T, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Nagaoka, M | 1 |
| Fukami, T | 1 |
| Kisui, F | 1 |
| Yamada, T | 1 |
| Sakai, Y | 1 |
| Tashiro, K | 1 |
| Ogiso, T | 1 |
| Konishi, K | 1 |
| Honda, S | 1 |
| Hirosawa, K | 1 |
| Nakano, M | 1 |
| Nakajima, M | 1 |
| Hernandez-Bures, A | 1 |
| White, AG | 1 |
| Riordan, L | 1 |
| Fleseriu, M | 1 |
| Pivonello, R | 1 |
| Elenkova, A | 1 |
| Salvatori, R | 1 |
| Auchus, RJ | 1 |
| Feelders, RA | 1 |
| Geer, EB | 1 |
| Greenman, Y | 1 |
| Witek, P | 1 |
| Cohen, F | 1 |
| Biller, BMK | 1 |
| Sullivant, AM | 1 |
| Lathan, P | 1 |
| Delivanis, DA | 1 |
| Athimulam, S | 1 |
| Bancos, I | 1 |
| Chou, DW | 1 |
| Chung, KM | 1 |
| Lee, CT | 1 |
| Costenaro, F | 1 |
| Rodrigues, TC | 1 |
| Ferreira, NP | 1 |
| Costa, TG | 1 |
| Schuch, T | 1 |
| Boschi, V | 1 |
| Czepielewski, MA | 1 |
| Gallais, V | 1 |
| Lacour, JP | 1 |
| Ortonne, JP | 1 |
| Angeli, A | 1 |
| Masera, RG | 1 |
| Gatti, G | 1 |
| Portilla Sogorb, J | 1 |
| Plana, C | 1 |
| Mauri, M | 1 |
| Picó, A | 1 |
| White, MC | 1 |
| Kendall-Taylor, P | 1 |
| McCance, DR | 1 |
| Ritchie, CM | 1 |
| Sheridan, B | 1 |
| Atkinson, AB | 1 |
| Ahonen, P | 1 |
| Myllärniemi, S | 1 |
| Kahanpää, A | 1 |
| Perheentupa, J | 1 |
| Lamberts, SW | 1 |
| Best, TR | 1 |
| Jenkins, JK | 1 |
| Murphy, FY | 1 |
| Nicks, SA | 1 |
| Bussell, KL | 1 |
| Vesely, DL | 1 |
| Tucker, WS | 1 |
| Snell, BB | 1 |
| Island, DP | 1 |
| Gregg, CR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome[NCT01838551] | Phase 3 | 94 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The response to COR-003 is defined as mean UFC concentration ≤ULN following 6 months of maintenance phase therapy without a prior dose increase during that phase. The proportion of responders at the End of Maintenance Phase visit, following 6 months of treatment in the Maintenance Phase, for all dose groups combined was estimated using a generalized linear model with repeated measurements based on a binomial distribution with a logit link function and with region (US vs. non-US), concurrent CS medical conditions (diabetes [Yes/No], hypertension [Yes/No]), age (rounded median split based on the ITT population), sex, disease duration (years), prior CS medication (Yes/No), prior radiation therapy (Yes/No) as Baseline covariates and visit as an independent factor.~The least squares mean (LSMEAN) estimate of the UFC response after 6 months of treatment in the Maintenance Phase alongside its 95% Wald CI is presented." (NCT01838551)
Timeframe: 6 months of maintenance phase therapy without a prior dose increase during that phase
| Intervention | proportion of subjects meeting endpoint (Least Squares Mean) |
|---|---|
| Levoketoconazole All Doses | .30 |
2 reviews available for ketoconazole and Adrenal Gland Hypofunction
| Article | Year |
|---|---|
[Cutaneous pigmentation disorders in human immunodeficiency virus infection].
Topics: Acquired Immunodeficiency Syndrome; Adrenal Insufficiency; Antiviral Agents; Bleomycin; Clofazimine; | 1992 |
[Mycoses and adrenocortical function. New pathogenetic aspects of adrenal hypofunction].
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Adrenal Glands; Adrenal Insufficiency; | 1991 |
2 trials available for ketoconazole and Adrenal Gland Hypofunction
| Article | Year |
|---|---|
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
Topics: Adolescent; Adrenal Insufficiency; Adult; Aged; Alanine Transaminase; Chemical and Drug Induced Live | 2019 |
Ketoconazole is effective against the chronic mucocutaneous candidosis of autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED).
Topics: Adolescent; Adrenal Insufficiency; Adult; Autoimmune Diseases; Candidiasis; Candidiasis, Chronic Muc | 1986 |
12 other studies available for ketoconazole and Adrenal Gland Hypofunction
| Article | Year |
|---|---|
Arylacetamide deacetylase knockout mice are sensitive to ketoconazole-induced hepatotoxicity and adrenal insufficiency.
Topics: Adrenal Insufficiency; Animals; Area Under Curve; Carboxylic Ester Hydrolases; Chemical and Drug Ind | 2022 |
Presumptive iatrogenic hypoadrenocorticism induced by high-dose ketoconazole administration in a dog.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Animals; Antifungal Agents; Dermatomycoses; Dog | 2019 |
Ketoconazole-induced transient hypoadrenocorticism in a dog.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Animals; Dog Diseases; Dogs; Female; Ketoconazol | 2020 |
Modern Management of Mild Autonomous Cortisol Secretion.
Topics: 14-alpha Demethylase Inhibitors; Adrenal Cortex Neoplasms; Adrenal Insufficiency; Adrenalectomy; Adr | 2019 |
Prototheca wickerhamii cutaneous and systemic infections.
Topics: Adrenal Insufficiency; Aged, 80 and over; Cytochrome P-450 CYP3A; Fever; Humans; Infections; Ketocon | 2014 |
Pseudotumor cerebri during Cushing's disease treatment with ketoconazole.
Topics: Adrenal Insufficiency; Child; Diagnosis, Differential; Female; Humans; Ketoconazole; Pituitary ACTH | 2011 |
[Adrenal gland insufficiency induced by ketoconazole in a patient with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adrenal Insufficiency; Adult; Humans; Ketoconazole; Male | 1991 |
Adrenal hypofunction in patients taking ketoconazole.
Topics: Adrenal Insufficiency; Humans; Hydrocortisone; Ketoconazole; Male; Prostatic Neoplasms | 1985 |
Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole.
Topics: Acute Disease; Adrenal Insufficiency; Adult; Chemical and Drug Induced Liver Injury; Cushing Syndrom | 1987 |
[Adrenal cortex insufficiency caused by drugs].
Topics: Adrenal Insufficiency; Etomidate; Humans; Ketoconazole | 1987 |
Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy.
Topics: Adrenal Insufficiency; Blastomycosis; Female; Glucocorticoids; Humans; Ketoconazole; Lung Diseases, | 1987 |
Reversible adrenal insufficiency induced by ketoconazole.
Topics: 17-Hydroxycorticosteroids; Adrenal Insufficiency; Cortodoxone; Cosyntropin; Humans; Hydrocortisone; | 1985 |